8 results on '"Brotherton JML"'
Search Results
2. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
- Author
-
Shilling H, Garland SM, Atchison S, Cornall AM, Brotherton JML, Bateson D, McNamee K, Kaldor JM, Hocking JS, Chen MY, Fairley CK, McNulty A, Bell C, Marshall L, Ooi C, Skinner SR, Murray G, Molano M, Tabrizi S, and Machalek DA
- Subjects
- Adolescent, Adult, Australia epidemiology, Female, Humans, Papillomaviridae genetics, Prevalence, Risk Factors, Vaccination, Young Adult, Alphapapillomavirus, Papillomavirus Infections epidemiology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines
- Abstract
Background: In Australia, high and widespread uptake of the quadrivalent human papillomavirus (HPV) vaccine has led to substantial population-level reductions in the prevalence of quadrivalent vaccine targeted HPV genotypes 6/11/16/18 in women aged ≤ 35 years. We assessed risk factors for HPV detection among 18-35 year old women, 9-12 years after vaccine program introduction., Methods: Women attending health services between 2015 and 2018 provided a self-collected vaginal specimen for HPV genotyping (Roche Linear Array) and completed a questionnaire. HPV vaccination status was validated against the National Register. Adjusted odds ratios (aORs) and 95% confidence intervals (CI) were calculated for factors associated with HPV detection., Results: Among 1564 women (median age 24 years; IQR 21-27 years), Register-confirmed ≥ 1-dose vaccine coverage was highest at 69.3% and 68.1% among women aged 18-21 and 22-24 years respectively, decreasing to 42.9% among those aged 30-35 years. Overall prevalence of quadrivalent vaccine-targeted HPV types was very low (2.0%; 95% CI: 1.4-2.8%) and influenced only by vaccination status (5.5% among unvaccinated compared with 0.7% among vaccinated women; aOR = 0.13 (95% CI: 0.05-0.30)). Prevalence of remaining HPV types, at 40.4% (95% CI: 38.0-42.9%), was influenced by established risk factors for HPV infection; younger age-group (p-trend < 0.001), more recent (p < 0.001) and lifetime sexual partners (p-trend < 0.001), but not vaccination status. Prevalence of HPV31/33/45, which shared risk factors with that of non-vaccine targeted HPV types, was also lower among vaccinated (4%) compared with unvaccinated (7%) women (aOR = 0.51; 95% CI: 0.29-0.89), indicative of cross-protection., Conclusion: Vaccination has changed the epidemiology of HPV infection in Australian women, having markedly reduced the prevalence of vaccine-targeted types, including amongst women with known risk factors for infection. Vaccinated women appear to be benefiting from modest cross-protection against types 31/33/45 afforded by the quadrivalent HPV vaccine. These results reinforce the importance of HPV vaccination., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
3. School-based HPV vaccination positively impacts parents' attitudes toward adolescent vaccination.
- Author
-
Davies C, Stoney T, Hutton H, Parrella A, Kang M, Macartney K, Leask J, McCaffery K, Zimet G, Brotherton JML, Marshall HS, and Skinner SR
- Subjects
- Adolescent, Australia, Decision Making, Female, Health Knowledge, Attitudes, Practice, Humans, Male, Parents, Patient Acceptance of Health Care, Schools, Vaccination, Papillomavirus Infections prevention & control, Papillomavirus Vaccines
- Abstract
Introduction: This qualitative study aimed to explore parental attitudes, knowledge and decision-making about HPV vaccination for adolescents in the context of a gender-neutral school-based Australian National Immunisation Program (NIP)., Methods: Semi-structured interviews with parents of adolescents eligible for HPV vaccination were undertaken as part of an evaluation of a cluster-randomised controlled trial of a complex intervention in 40 schools (2013-2015). In this qualitative study, we purposively recruited a nested sample of parents from 11 schools across two Australian jurisdictions. Interviews explored parent knowledge and understanding of the HPV vaccine program; HPV vaccination decision-making; their adolescent's knowledge about HPV vaccination; and their adolescent's understanding about HPV vaccination, sexual awareness and behaviour. Transcripts were analysed using inductive and deductive thematic analysis., Results: Parents' of 22 adolescents had positive attitudes towards the program; the school-based delivery platform was the key driver shaping acceptance of and decision-making about HPV vaccination. They had difficulty recalling, or did not read, HPV vaccination information sent home. Some adolescents were involved in discussions about vaccination, with parents' responsible for ultimate vaccine decision-making. All parents supported in-school education for adolescents about HPV and HPV vaccination. Parents' knowledge about HPV vaccination was limited to cervical cancer and was largely absent regarding vaccination in males., Conclusions: Parents' positive attitudes towards the NIP and inclusion of the HPV vaccine is central to their vaccine decision-making and acceptance. More intensive communication strategies including school education opportunities are required to improve parents' knowledge of HPV-related disease and to promote vaccine decision-making with adolescents., Competing Interests: Declaration of Competing Interest SRS’s institution received funding from Seqirus and Merck for her contribution to educational activities for the general public and professionals. HM is an investigator on clinical vaccine trials sponsored by Industry. Her institution receives funding from GSK, Pfizer and Sanofi-Pasteur for Investigator led studies. She does not receive any personal payments from Industry. TS has received a consultancy services fee from GSK Biologicals for review of a new simplified informed consent form. She has received travel support to attend investigator meetings conducted by GSK Biologicals, Novavax Inc., Janssen Cilag Pty Ltd and Merck Sharp & Dohme. She has been an investigator on clinical vaccine trials sponsored by Industry (GSK Biologicals, Novavax, Merck Sharpe & Dohme, Janssen Cilag Pty Ltd, MedImmune, Pfizer) for which her institution received funding. GZ has received honoraria from Sanofi Pasteur for work on the Adolescent Immunization Initiative and honoraria and travel support from Merck for consultations on HPV vaccination. GZ has received research funding from Merck, administered by his institution, related to HPV vaccination., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
4. HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination.
- Author
-
Cornall AM, Saville M, Pyman J, Callegari ET, Tan FH, Brotherton JML, Malloy MJ, Tabrizi SN, Wrede CD, and Garland SM
- Subjects
- Adolescent, Adult, Female, Genotype, Human papillomavirus 16 genetics, Human papillomavirus 18 genetics, Humans, Papillomaviridae genetics, Prevalence, Vaccination, Victoria epidemiology, Young Adult, Papillomavirus Infections epidemiology, Papillomavirus Infections prevention & control, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms prevention & control
- Abstract
Objectives: Using laser capture microdissection (LCM) and sensitive human papillomavirus (HPV) genotyping, we aimed to determine the distribution of vaccine-preventable types in cervical intraepithelial neoplasia grade 3 (CIN3) lesions and adenocarcinoma in situ (AIS) in young women in Victoria, Australia, offered catch-up HPV vaccination, as a baseline for ongoing vaccine impact monitoring. We also compared findings with available pre-vaccination estimates from women with HPV detected on concurrently-collected cytology samples., Methods: Consecutive histologically-confirmed CIN3/AIS biopsies were collected between May 2011 and December 2014 from vaccine-eligible women (born after 30th June 1981). Genotypes present in whole tissue sections (WTS) were determined by a sensitive reverse hybridisation assay; RHA kit HPV SPF10-LiPA25, v1 (Labo Bio-medical Products). Where multiple genotypes were detected, lesions were isolated using LCM and genotyped. Cervical cytology samples from a pre-vaccine cohort had been previously collected and genotyped using HPV Linear Array HPV Genotyping Test (Roche Diagnostics). Mixed-genotype detections in this cohort were resolved to single-lesion-attributable genotypes using hierarchical attribution., Results: Overall, 213 and 530 cases were included from pre- and post-vaccine time-periods, respectively. In 18-25 year-olds, the proportion of HPV16/18-positive CIN3/AIS decreased significantly over time from 69% in 2001-2005 (pre-vaccine), to 62% in 2011-2012 (post-vaccine), to 47% in 2013-2014 (p-trend = 0.004). There was no significant change in HPV16/18 in 26-32 year-olds (p-trend = 0.15). In 2013/14, nonavalent vaccine types accounted for 80% of CIN3/AIS in 18-25 year old women and 90% in 26-32 year old women., Conclusion: Four to 8 years following implementation of HPV vaccination in Australia, approximately 70% of CIN3/AIS in young women was due to HPV16/18. Our data, despite some limitations due to change in methods between pre- and post-vaccine periods, suggests that for vaccine-eligible women aged 18-25 at the time of biopsy, the proportion of HPV16/18-attributable CIN3/AIS lesions is significantly declining post-vaccination., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Professor Suzanne Garland, has received Grants to her institution to measure vaccine impact and effectiveness in a young women’s study and as an Investigator Initiated grant from Merck. She has received speaking fees from MSD for work performed in her personal time and is a member of the Merck HPV Global Advisory Board. Alyssa Cornall is an investigator on a research study funded by Seqirus (cervical cancer typing study) and has received an educational grant from Seqirus. Julia Brotherton reports employment as the Medical Director of the National HPV Vaccination Program Register, which was owned and funded by the Australian Government Department of Health. Julia Brotherton and Sepehr Tabrizi have been investigators on investigator-initiated HPV epidemiology studies which have received unrestricted partial funding for laboratory components from Seqirus (cervical cancer typing study) and Merck (recurrent respiratory papillomatosis study) but have never received any personal financial benefits. Sepehr Tabrizi also reports grants from The Royal Women's Hospital during the conduct of the study. C. David Wrede is the Deputy Chair of VCS Foundation Pty Ltd and a Board member since 2010, he has received sponsorship and honoraria from Seqirus. All authors attest they meet the ICMJE criteria for authorship., (Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
5. Assessment of attribution algorithms for resolving CIN3-related HPV genotype prevalence in mixed-genotype biopsy specimens using laser capture microdissection as the reference standard.
- Author
-
Cornall AM, Brotherton JML, Callegari ET, Tan FH, Saville M, Pyman J, Phillips S, Malloy MJ, Tabrizi SN, and Garland SM
- Subjects
- Adolescent, Adult, Algorithms, Australia, Biopsy, Female, Genotype, Humans, Laser Capture Microdissection, Papillomaviridae genetics, Prevalence, Reference Standards, Young Adult, Papillomavirus Infections epidemiology, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Dysplasia
- Abstract
To make accurate determinations regarding potential and actual impact of HPV vaccine programs, precise estimates of genotype-specific contributions to disease are required for pre- and post-vaccine populations. Definitive determination of lesion-specific genotypes, particularly where multiple genotypes are detected in a sample, can be technically demanding and resource intensive; therefore, most prevalence studies use mathematical algorithms to adjust for multiple genotype detections. There are currently several algorithms, which can produce genotype estimates within a wide range of variability. The use of these for cervical cytology samples has recently been assessed for accuracy against a definitive reference standard, but none have yet been assessed for multiple-genotype-containing whole biopsy specimens. Using laser capture microdissection (LCM) on biopsy samples, lesion-specific genotype prevalence data were generated for a cohort of 516 young Australian women (aged 18-32 years) with cervical intraepithelial neoplasia grade 3 or adenocarcinoma in situ. Using whole tissue section genotype data from the same cohort, including 71 (13.7%) with multiple genotypes, lesion-associated genotype prevalence was estimated using four different attribution algorithms. The proportion of lesions attributable to HPV16 and HPV18 by LCM were 58.4% and 5%, respectively; hierarchical, proportional, single type/minimum and any type/maximum attribution estimates were comparable across genotypes. For analyses utilising whole tissue biopsy cervical specimens, attribution estimates are appropriate for estimating the proportional contribution of individual genotypes to lesions in a population., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
6. Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening.
- Author
-
Shilling H, Murray G, Brotherton JML, Hawkes D, Saville M, Sivertsen T, Chambers I, Roberts J, Farnsworth A, Garland SM, Hocking JS, Kaldor J, Guy R, Atchison S, Costa AM, Molano M, and Machalek DA
- Subjects
- Adolescent, Adult, Chlamydia Infections diagnosis, Early Detection of Cancer, Female, Humans, New South Wales epidemiology, Papillomavirus Vaccines, Prevalence, Victoria epidemiology, Young Adult, Alphapapillomavirus isolation & purification, Papillomavirus Infections diagnosis, Papillomavirus Infections epidemiology
- Abstract
Introduction: Australia has recently implemented major changes in cervical cancer prevention policies including introduction of primary human papillomavirus (HPV) screening starting at age 25, and replacement of the quadrivalent HPV vaccine with the nonavalent vaccine in the national school-based program. We assessed the feasibility and utility of conducting HPV testing in residual clinical specimens submitted for routine Chlamydia trachomatis screening, as a means of tracking HPV vaccine program impact among young sexually active women., Methods: De-identified residual specimens from women aged 16-24 years submitted for chlamydia testing were collected from three pathology laboratories in Victoria and New South Wales. Limited demographic information, and chlamydia test results were also collected. Patient identifiers were sent directly from the laboratories to the National HPV Vaccination Program Register, to obtain HPV vaccination histories. Samples underwent HPV genotyping using Seegene Anyplex II HPV 28 assay., Results: Between April and July 2018, 362 residual samples were collected, the majority (60.2%) of which were cervical swabs. Demographic data and vaccination histories were received for 357 (98.6%) women (mean age 21.8, SD 2.0). Overall, 65.6% of women were fully vaccinated, 9.8% partially, and 24.7% unvaccinated. The majority (86.0%) resided in a major city, 35.9% were classified in the upper quintile of socioeconomic advantage and chlamydia positivity was 7.8%.The prevalence of quadrivalent vaccine-targeted types (HPV6/11/16/18) was 2.8% (1.5-5.1%) overall with no differences by vaccination status (p = 0.729). The prevalence of additional nonavalent vaccine-targeted types (HPV31/33/45/52/58) was 19.3% (15.6-23.8%). One or more oncogenic HPV types were detected in 46.8% (95% CI 41.6-52.0%) of women., Conclusions: HPV testing of residual chlamydia specimens provides a simple, feasible method for monitoring circulating genotypes. Applied on a larger scale this method can be utilised to obtain a timely assessment of nonavalent vaccine impact among young women not yet eligible for cervical screening., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: DAM reports travel grants from Seqirus, travel funding and honoraria to her institute from Merck Sharp & Dohme (MSD), outside the submitted work. JMLB, MS and DH are investigators on the Compass trial for which VCS Foundation has received kits and partial funding from Roche. VCS Pathology has also received free test kits from Roche, Seegene, Cepheid, and Becton Dickinson. JMLB, MS and SMG were investigators on a cervical cancer typing study with laboratory testing funded by Seqirus more than three years ago. JMLB and SMG were investigators on a recurrent respiratory papillomatosis surveillance study partially funded by an investigator initiated grant from MSD more than three years ago. SMG has received grants to her institution from Merck and GSK (GlaxoSmithKline) to perform phase 3 clinical vaccine trials. She has received speaking fees from MSD for work performed in her personal time and Merck paid for travel and accommodation to present at Global HPV Advisory board meetings. DAM, JMK and RG are investigators on a genital warts surveillance grant funded by Sequiris. All other authors declare no conflicts of interest., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
7. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study.
- Author
-
McGregor S, Saulo D, Brotherton JML, Liu B, Phillips S, Skinner SR, Luey M, Oliver L, Stewart M, Tabrizi SN, Garland S, and Kaldor JM
- Subjects
- Adolescent, Adult, Australia epidemiology, Cross-Sectional Studies, Female, Genotype, Humans, Papillomaviridae classification, Papillomaviridae genetics, Papillomavirus Infections complications, Population Groups, Prevalence, Young Adult, Australian Aboriginal and Torres Strait Islander Peoples, Cervix Uteri virology, Papillomaviridae isolation & purification, Papillomavirus Infections epidemiology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines administration & dosage
- Abstract
Background: Cervical cancer occurrence and mortality are strongly correlated with socioeconomic disadvantage, largely due to unequal access to screening and treatment. Universal human papillomavirus (HPV) vaccination provides the opportunity to greatly reduce this global health disparity. Australian Indigenous women have substantially higher rates of cervical cancer than non-Indigenous women, primarily due to under-screening. We investigated HPV infection rates in Indigenous women 7 years after implementation of the national HPV vaccination program., Methods: We used a repeat cross-sectional design, with the baseline being provided by an HPV prevalence survey among Indigenous women attending clinics for cervical cytology screening, prior to the start of the vaccination program in 2007. We returned to clinics in four locations during 2014-15, and invited women aged 18-26 years attending for screening to provide a cervical specimen for HPV testing, as well as to complete a short questionnaire and consent to allow access of their records in the National HPV Vaccination Program Register. We used well-established laboratory methods to test specimens for specific HPV genotypes., Results: A total of 142 women were recruited at participating sites and compared to 155 who had been recruited at the same locations in the 2007 pre-vaccine survey. The two groups were identical in regard to age, with the more recent group having a higher proportion of hormonal contraception users, and a lower proportion of smokers. The proportion found to have any HPV type fell from 58 to 36% with the decline being entirely due to reductions in vaccine types, which fell by 94% from 24 to 1.4%., Conclusion: Australia's national HPV vaccination program appears to be successfully protecting a very high proportion of Indigenous women against vaccine targeted HPV types, who have in the past been at elevated risk of cervical cancer., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
8. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
- Author
-
Garland SM, Cornall AM, Brotherton JML, Wark JD, Malloy MJ, and Tabrizi SN
- Subjects
- Adolescent, Adult, Alphapapillomavirus immunology, Alphapapillomavirus pathogenicity, Cervix Uteri virology, Female, Human papillomavirus 16 genetics, Human papillomavirus 16 immunology, Humans, Male, Papillomavirus Infections epidemiology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines immunology, Prevalence, Sexual Behavior, Socioeconomic Factors, Victoria epidemiology, Alphapapillomavirus genetics, Immunization Programs statistics & numerical data, Papillomavirus Infections virology, Papillomavirus Vaccines therapeutic use
- Abstract
Objectives: The VACCINE [Vaccine Against Cervical Cancer Impact and Effectiveness] study evaluated the prevalence of quadrivalent vaccine-targeted human papillomavirus (HPV) genotypes (HPV 6, 11, 16, 18) amongst young women of vaccine-eligible age., Methods: Between October 2011 - June 2015, women aged 18-25 years from Victoria, Australia, were recruited through targeted advertising on the social networking website Facebook. Participants completed an online questionnaire and provided a self-collected vaginal swab for HPV DNA detection and genotyping (Linear Array HPV genotyping assay). Self-reported HPV vaccination details were verified with the National HPV Vaccination Program Register (NHVPR)., Results: Of 1223 who agreed to participate, 916 (74.9%) completed the survey and, for 1007 (82.3%) sexually-active participants, 744 (73.9%) returned the self-collected swab, of which 737 contained detectable DNA. 184/737 (25.0%) were positive for HPV. Vaccine-targeted HPV genotypes were detected in only 13 (1.7%) women: 11 HPV 16 (six vaccinated after sexual debut, five unvaccinated) and two HPV 6. Prevalence of any of HPV 31/33/45 collectively was 2.9%, varying significantly by vaccination status (fully 2.0%, unvaccinated 6.8%; p = 0.01). Vaccination rates among the sexually-active cohort were high, with 65.6%, 71.6% and 74.2% of participants having received three, at least two or at least one dose of vaccine, respectively. Of women self-reporting HPV vaccination, the NHVPR confirmed one or more doses were received in 90%. Strong associations were observed between vaccination status, age, language spoken at home and country of birth, as well as between HPV detection and the number of male sexual partners., Conclusion: Surveillance five to eight years' post-initiation of a national HPV vaccination program demonstrated a consistent and very low prevalence of vaccine-related HPV genotypes and some evidence of cross protection against related types amongst vaccine-eligible women from Victoria, Australia., (Copyright © 2018. Published by Elsevier Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.